Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)—an individual participant data meta-analysisLisa G Schoof, Jeppe Romme Christensen, Emmanuelle Le Page et al.|Multiple Sclerosis and Related Disorders|2025Cited by 3